New hope for elderly lymphoma patients: triple-drug combo targets aggressive cancer
NCT ID NCT07415980
First seen Feb 19, 2026 · Last updated May 08, 2026 · Updated 13 times
Summary
This study tests a three-drug combination (polatuzumab vedotin, rituximab, and chidamide) in older adults (70+ or frail 60-69) with a specific type of aggressive lymphoma called double-expressor DLBCL. The goal is to see if the combo is safe and effective at shrinking tumors. About 68 participants will receive the treatment, and researchers will monitor side effects and cancer response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOUBLE EXPRESSOR DLBCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.